How would you integrate all the currently available tests — NGS-based mutational profiles and burden and IHC biomarkers — to stratify patients into cohorts likely to be responsive to PD-1 checkpoint inhibitors?

How would you integrate all the currently available tests — NGS-based mutational profiles and burden and IHC biomarkers — to stratify patients into cohorts likely to be responsive to PD-1 checkpoint inhibitors?

How would you integrate all the currently available tests — NGS-based mutational profiles and burden and IHC biomarkers — to stratify patients into cohorts likely to be responsive to PD-1 checkpoint inhibitors?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA